Castle Net Receivables from 2010 to 2025

CSTL Stock  USD 20.84  0.14  0.67%   
Castle Biosciences Net Receivables yearly trend continues to be quite stable with very little volatility. Net Receivables may rise above about 53.8 M this year. From the period between 2010 and 2025, Castle Biosciences, Net Receivables regression line of its data series had standard deviation of  16,889,492 and standard deviation of  16,889,492. View All Fundamentals
 
Net Receivables  
First Reported
2018-03-31
Previous Quarter
50.3 M
Current Value
51.2 M
Quarterly Volatility
13.8 M
 
Covid
Check Castle Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Castle Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 3.5 M, Net Interest Income of 13 M or Interest Income of 13.6 M, as well as many indicators such as Price To Sales Ratio of 2.12, Dividend Yield of 0.0 or PTB Ratio of 1.71. Castle financial statements analysis is a perfect complement when working with Castle Biosciences Valuation or Volatility modules.
  
Check out the analysis of Castle Biosciences Correlation against competitors.
For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.

Latest Castle Biosciences' Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Castle Biosciences over the last few years. It is Castle Biosciences' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Castle Biosciences' overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

Castle Net Receivables Regression Statistics

Arithmetic Mean16,298,260
Geometric Mean10,481,597
Coefficient Of Variation103.63
Mean Deviation12,820,700
Median12,089,719
Standard Deviation16,889,492
Sample Variance285.3T
Range49.1M
R-Value0.85
Mean Square Error85.3T
R-Squared0.72
Significance0.000032
Slope3,012,026
Total Sum of Squares4278.8T

Castle Net Receivables History

202553.8 M
202451.2 M
202338.3 M
202223.5 M
202117.3 M
202012.8 M
201914.6 M

About Castle Biosciences Financial Statements

Castle Biosciences investors utilize fundamental indicators, such as Net Receivables, to predict how Castle Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Receivables51.2 M53.8 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Castle Biosciences is a strong investment it is important to analyze Castle Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Castle Biosciences' future performance. For an informed investment choice regarding Castle Stock, refer to the following important reports:
Check out the analysis of Castle Biosciences Correlation against competitors.
For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.93)
Earnings Share
0.62
Revenue Per Share
11.955
Quarterly Revenue Growth
0.305
Return On Assets
0.011
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.